BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32588075)

  • 1. Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?
    High RA; Winkelman W; Panza J; Sanderson DJ; Yuen H; Halder G; Shaver C; Bird ET; Rogers RG; Danford JM
    Int Urogynecol J; 2021 Jan; 32(1):149-157. PubMed ID: 32588075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study.
    Myer ENB; Petrikovets A; Slocum PD; Lee TG; Carter-Brooks CM; Noor N; Carlos DM; Wu E; Van Eck K; Fashokun TB; Yurteri-Kaplan L; Chen CCG
    Am J Obstet Gynecol; 2018 Jul; 219(1):78.e1-78.e9. PubMed ID: 29630890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacral neuromodulation for symptomatic chronic urinary retention in females: do age and comorbidities make a difference?
    High RA; Winkelman W; Panza J; Sanderson DJ; Yuen H; Halder GE; Shaver C; Bird ET; Rogers RG; Danford JM
    Int Urogynecol J; 2021 Oct; 32(10):2703-2715. PubMed ID: 32902761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment does not impact sacral neuromodulation implant rates for overactive bladder.
    Zillioux J; Lewis KC; Hettel D; Goldman HB; Vasavada SP; Gill BC
    Neurourol Urodyn; 2023 Mar; 42(3):623-630. PubMed ID: 36701189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statewide Success of Staged Sacral Neuromodulation for the Treatment of Urinary Complaints in California (2005-2011).
    Dobberfuhl AD; Mahal A; Dallas KB; Choi KM; Comiter CV; Elliott CS
    Female Pelvic Med Reconstr Surg; 2020 Jul; 26(7):437-442. PubMed ID: 30059438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
    Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
    J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
    Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
    J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraoperative Predictors of Sacral Neuromodulation Implantation and Treatment Response: Results From the ROSETTA Trial.
    Gill BC; Thomas S; Barden L; Jelovsek JE; Meyer I; Chermansky C; Komesu YM; Menefee S; Myers D; Smith A; Mazloomdoost D; Amundsen CL
    J Urol; 2023 Aug; 210(2):331-340. PubMed ID: 37126070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset of Action of Sacral Neuromodulation in Lower Urinary Tract Dysfunction-What is the Optimal Duration of Test Stimulation?
    Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; van Kerrebroeck P
    J Urol; 2018 Jun; 199(6):1584-1590. PubMed ID: 29291416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
    Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
    World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-human implantation of a mid-field powered neurostimulator at the sacral nerve: Results from an acute study.
    van Kerrebroeck PEVA; Reekmans M; van Koeveringe GA; Yeh AJ; Fayram TA; Sharan AD; Comiter CV
    Neurourol Urodyn; 2019 Aug; 38(6):1669-1675. PubMed ID: 31107559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacral Neuromodulation: Determining Predictors of Success.
    Morgan TN; Pace N; Mohapatra A; Ren D; Kunkel G; Tennyson L; Shepherd JP; Chermansky CJ
    Urology; 2021 Jul; 153():124-128. PubMed ID: 32619594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific Changes in Brain Activity during Urgency in Women with Overactive Bladder after Successful Sacral Neuromodulation: A Functional Magnetic Resonance Imaging Study.
    Weissbart SJ; Bhavsar R; Rao H; Wein AJ; Detre JA; Arya LA; Smith AL
    J Urol; 2018 Aug; 200(2):382-388. PubMed ID: 29630979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
    Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
    Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Age and Comorbidities on Use of Sacral Neuromodulation.
    Faris AER; Gill BC; Pizarro-Berdichevsky J; Dielubanza E; Clifton MM; Okafor H; Goldman HB; Moore CK; Rackley RR; Vasavada SP
    J Urol; 2017 Jul; 198(1):161-166. PubMed ID: 28192077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience.
    Groen LA; Hoebeke P; Loret N; Van Praet C; Van Laecke E; Ann R; Vande Walle J; Everaert K
    J Urol; 2012 Oct; 188(4):1313-7. PubMed ID: 22902022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
    Parnell BA; Howard JF; Geller EJ
    Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
    Chughtai B; Clemens JQ; Thomas D; Sun T; Ghomrawi H; Sedrakyan A
    J Urol; 2020 Jan; 203(1):179-184. PubMed ID: 31347949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.